Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease.

ABSTRACT:

Background

The beneficial outcomes of ezetimibe plus statin therapy are well-established in coronary artery disease, but these remain unknown in lower extremity artery disease (LEAD).

Objectives

This study evaluated the efficacy of an intensified lipid-lowering strategy involving ezetimibe plus statins vs statin monotherapy for reducing major adverse limb events and mortality in patients with LEAD.

Methods

This retrospective analysis included patients aged ≥18 years diagnosed with LEAD from the TriNetX global health care database from 2013 to 2022, excluding those with recent acute coronary syndrome or stroke. The primary outcome was the 12-month cumulative incidence of major lower limb amputation and all-cause death as a composite endpoint. Propensity score matching

SUBMITTER: Iwasaki Y 

PROVIDER: S-EPMC12391692 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature